मलाशय का कैंसर (Rectal cancer)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
कहाँ जाना है
इस ट्रायल के लिए भारत में 8 अस्पताल मरीज़ों को ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…
स्पॉन्सर: Janssen Research & Development, LLC
NCT06750094 on ClinicalTrials.gov
रजिस्ट्री पर आखिरी बार 25 Sep 2026 को अपडेट किया गया · हमने 20 Oct 2026 को पढ़ा